Pyruvate kinase R (PKR) activating compositions

US12161634B2 · kind B2 · utility

Assignee

• Novo Nordisk Health Care AG · CH

Inventors

• George P. Luke · Clinton, US
• Sonia Rodriguez · Avon, US
• Hongwei Zhang · Tianjin, CN
• Shanming Kuang
• Yuwen Xu · 安丰镇, CN

Key dates

• Filing date: Sep 18, 2020
• Grant date: Dec 10, 2024
• Expiry date: Jun 12, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P7/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides crystalline solid forms, spray-dried dispersions and pharmaceutical compositions, including solid oral dosage forms, of (S)-1-(5-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2-phenylpropan-1-one (“Compound 1”), and preparation methods thereof.